We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Growth of Mantle Cell Lymphoma Slowed by Nanoparticle Transported siRNA

By LabMedica International staff writers
Posted on 13 Jan 2016
Cancer researchers have used targeted lipid-based nanoparticles to deliver particles of siRNA (short inhibiting RNA) to silence the gene for production of cyclin D1 in mantle cell lymphoma (MCL).

MCL is an aggressive B-cell lymphoma that over expresses cyclin D1 with relatively poor prognosis, and down-regulation of cyclin D1 using RNA interference (RNAi) has been suggested as a potential therapeutic approach to this malignancy. More...
Short inhibiting RNAs are members of the family of microRNAs, which are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.

Investigators at Tel Aviv University (Israel) prepared lipid-based nanoparticles (LNPs) coated with anti-CD38 monoclonal antibodies that were specifically taken up by human MCL cells in the bone marrow of xenografted mice.

Results published in the December 23, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) revealed that when loaded with siRNAs against cyclin D1, CD38-targeted LNPs induced gene silencing in MCL cells and prolonged survival of tumor-bearing mice with no observed adverse effects.

"MCL has a genetic hallmark," said senior author Dr. Dan Peer, professor of cell research and immunology at Tel Aviv University. "In 85% of cases, the characteristic that defines this aggressive and prototypic B-cell lymphoma is the heightened activity of the gene CCND1, which leads to the extreme overexpression—a 3,000 to 15,000-fold increase—of cyclin D1, a protein that controls the proliferation of cells. Downregulation of cyclin D1 using siRNAs is a potential therapeutic approach to this malignancy."

"In MCL, cyclin D1 is the exclusive cause of the over-production of B lymphocytes, the cells responsible for generating antibodies," said Dr. Peer. "This makes the protein a perfect target for RNA therapy by siRNAs. Normal, healthy cells do not express the gene, so therapies that destroy the gene will only attack cancer cells. The RNA interference we have developed targets the faulty cyclin D1 within the cancerous cells. And when the cells are inhibited from proliferating, they sense they are being targeted and begin to die off."

Related Links:

Tel Aviv University



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Test
Allplex HPV28 Detection
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.